H&R KGaA Reflects Positive Sales Trends in Third Quarter
Recently, H&R GmbH & Co. KGaA, widely recognized as H&R KGaA, shared an encouraging update on their sales and earnings progress towards the tail end of the third quarter. Their initial forecasts conveyed an operating result (EBITDA) of €24.8 million, a noteworthy figure that, although lower than the previous year's €27.2 million for the same quarter, represents the most robust momentum the company has seen this year thus far.
Quarterly Financial Overview
In addition to EBITDA, H&R KGaA reported an EBIT of €9 million, down from €13 million in Q3 a year earlier. However, the earnings before taxes (EBT) experienced a decline to €5.8 million compared to €9.6 million previously. The net income that shareholders can attribute was recorded at €3.5 million, noticeably lower than the €7.6 million achieved during the same quarter last year. Despite these challenges, their revenue displayed a slight uptick, increasing to €338.1 million from €337.2 million.
Performance Analysis for 2024
In the first nine months of 2024, H&R KGaA maintained a fairly stable EBITDA of €65.9 million, only a minor decrease from €66.6 million during the same time frame last year. This stability comes alongside a dip in sales revenues, which fell to €1,013.6 million from €1,036.8 million. Notably, increased depreciation and amortization expenses of approximately 6.5% year-over-year corresponded with a drop in EBIT, reported at €20.6 million compared to €24.1 million in 2023. EBT similarly saw a reduction, declining from €15.2 million to €11.1 million, while consolidated net income for shareholders came in at €6.3 million, down from €11.3 million the year prior.
Segment Performance Insights
The ChemPharm REFINING segment reversed its earlier trends, contributing significantly to earnings in 2024. The EBITDA for this segment in Q3 was €15.3 million, which, though lower than €20.9 million from the same period in 2023, indicated stability with €35.8 million for the nine-month tally, down from €43.2 million last year. However, sales in this area reached €621.8 million over nine months, a slight reduction from €634.1 million a year ago.
International Activities and Sales
Positive signs emerged from the international activities within the ChemPharm SALES segment, which recorded an operating result of €9.7 million in Q3, up from €8.1 million during the same timeframe last year, while also achieving an increase to €30.8 million over the nine-month period from €21.9 million in 2023. Yet, it is essential to note that revenue fell to €370.2 million over nine months, along with Q3 revenue decreasing to €126.6 million from €129.0 million the prior year.
The Challenges in the PLASTICS Segment
On another front, the PLASTICS segment faced challenges, reporting a reduced operating result of €1.7 million for the nine months, however, it did contribute positively with €0.5 million during Q3. Sales figures for this segment also varied significantly, tallying at €36.3 million for the nine-month period and €12.1 million for Q3, reflecting the ongoing difficulties within the automotive industry.
Cash Flow and Financial Stability
Operating cash flow for the first nine months measured at €53.8 million, which was weaker than the previous year's result of €73.0 million, largely due to escalated interest and income tax liabilities. Notably, the third quarter demonstrated remarkable recovery with an operating cash flow of €48.3 million, while free cash flow reached €36.2 million. As of September 30, 2024, the company's total assets displayed growth to €943.6 million from the €903.2 million recorded at the end of the previous year. Shareholder equity also increased to €464.5 million from €457.6 million, reflecting a solid equity ratio of 49.2%.
Future Expectations
As H&R KGaA continues to navigate through the complexities of the current market landscape, they remain optimistic about achieving results comparable to last year and expect to meet the outlined forecasts. Further insights into the company's performance in 2024 will be revealed with the release of final financial figures in the quarterly statement expected mid-November.
Frequently Asked Questions
What are the key financial results for H&R KGaA in Q3?
H&R KGaA reported an EBITDA of €24.8 million, an EBIT of €9 million, and a net income of €3.5 million for Q3.
How does H&R KGaA's performance compare to the previous year?
Overall, there is a decline in earnings compared to the previous year, yet some segments showed recovery in operational results.
Which segment contributed significantly to earnings in 2024?
The ChemPharm REFINING segment reversed its previous trend, significantly contributing to earnings in 2024.
What does the future look like for H&R KGaA?
H&R KGaA maintains a positive outlook and aims to achieve similar results to the previous year.
When will H&R KGaA release final financial figures?
The company will publish the final financial figures in their quarterly statement on November 14, 2024.
